TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Stock Price & Overview
NASDAQ:TCBP • US87807D6085
Current stock price
The current stock price of TCBP is 0.5 USD. Today TCBP is down by -67.53%. In the past month the price decreased by -80%. In the past year, price decreased by -99.79%.
TCBP Key Statistics
- Market Cap
- 5.13M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.21
- Dividend Yield
- N/A
TCBP Stock Performance
TCBP Stock Chart
TCBP Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to TCBP. When comparing the yearly performance of all stocks, TCBP is a bad performer in the overall market: 99.89% of all stocks are doing better.
TCBP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TCBP. TCBP has a bad profitability rating. Also its financial health evaluation is rather negative.
TCBP Earnings
TCBP Forecast & Estimates
7 analysts have analysed TCBP and the average price target is 48.96 USD. This implies a price increase of 9692% is expected in the next year compared to the current price of 0.5.
For the next year, analysts expect an EPS growth of 96.52% and a revenue growth -100% for TCBP
TCBP Groups
Sector & Classification
TCBP Financial Highlights
Over the last trailing twelve months TCBP reported a non-GAAP Earnings per Share(EPS) of -4.21. The EPS decreased by -27216.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.77% | ||
| ROE | -293.88% | ||
| Debt/Equity | 1.07 |
TCBP Ownership
TCBP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TCBP
Company Profile
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 41 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - phase IIb/III pivotal trial in treatment of acute myeloid leukemia using its proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product is TCB-008. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, the Company is also developing an expanded platform for TCB-008 use case in anti-fungal, anti-viral and anti-microbial diseases. Its unmodified cell therapy, used in the treatment of acute myeloid leukemia, is supplied under the name OmnImmune. The company is also developing a range of genetically modified CAR-T products for the treatment of solid cancers.
Company Info
IPO: 2022-02-23
TC BIOPHARM HOLDINGS PLC-ADR
Maxim 1, 2 Parklands Way, Holytown
Motherwell GB
Employees: 41
Phone: 441414337557
TC BIOPHARM HOLDINGS PLC-ADR / TCBP FAQ
What does TCBP do?
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 41 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - phase IIb/III pivotal trial in treatment of acute myeloid leukemia using its proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product is TCB-008. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, the Company is also developing an expanded platform for TCB-008 use case in anti-fungal, anti-viral and anti-microbial diseases. Its unmodified cell therapy, used in the treatment of acute myeloid leukemia, is supplied under the name OmnImmune. The company is also developing a range of genetically modified CAR-T products for the treatment of solid cancers.
What is the current price of TCBP stock?
The current stock price of TCBP is 0.5 USD. The price decreased by -67.53% in the last trading session.
Does TC BIOPHARM HOLDINGS PLC-ADR pay dividends?
TCBP does not pay a dividend.
What is the ChartMill technical and fundamental rating of TCBP stock?
TCBP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about TC BIOPHARM HOLDINGS PLC-ADR (TCBP) stock?
7 analysts have analysed TCBP and the average price target is 48.96 USD. This implies a price increase of 9692% is expected in the next year compared to the current price of 0.5.
Can you provide the PE ratio for TCBP stock?
TC BIOPHARM HOLDINGS PLC-ADR (TCBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.21).